An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
Status: | Completed |
---|---|
Conditions: | Osteoporosis, Postmenopausal Syndrome |
Therapuetic Areas: | Endocrinology, Rheumatology |
Healthy: | No |
Age Range: | 55 - 90 |
Updated: | 11/10/2018 |
Start Date: | January 31, 2013 |
End Date: | May 14, 2015 |
An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With Romosozumab in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy
The primary objective of the study was to evaluate the effect of 12 months of treatment with
romosozumab compared with teriparatide on total hip bone mineral density (BMD) in
postmenopausal women with osteoporosis who were previously treated with bisphosphonate
therapy.
romosozumab compared with teriparatide on total hip bone mineral density (BMD) in
postmenopausal women with osteoporosis who were previously treated with bisphosphonate
therapy.
Inclusion Criteria:
- Postmenopausal women, aged ≥ 55 to ≤ 90.
- Received oral bisphosphonate therapy for at least 3 years immediately prior to
screening
- BMD T-score ≤ -2.50 at the lumbar spine, total hip or femoral neck
- History of nonvertebral fracture after age 50, or vertebral fracture.
Exclusion Criteria:
- Use of other agents affecting bone metabolism including Strontium ranelate, fluoride
(for osteoporosis), odanacatib (MK-0822) or any other cathepsin K inhibitor, IV
bisphosphonates, denosumab, teriparatide (TPTD) or any parathyroid hormone (PTH)
analogs, Systemic oral or transdermal estrogen, selective estrogen receptor modulators
(SERMs), activated vitamin D3, vitamin K2, calcitonin, tibolone, cinacalcet, systemic
glucocorticosteroids:
- History of metabolic or bone disease (except osteoporosis) that may interfere with the
interpretation of study results, such as sclerosteosis, Paget's disease, rheumatoid
arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing
spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome.
- Vitamin D insufficiency, defined as 25 (OH) vitamin D levels < 20 ng/mL, as determined
by the central laboratory.
- Current hyper- or hypocalcemia
- Current, uncontrolled hyper- or hypothyroidism
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Ciudad Autónoma de Buenos Aires, Buenos Aires
Click here to add this to my saved trials
Click here to add this to my saved trials